Eur J Pharmacol GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway
This is consistent, the team said, with the prevailing hypothesis suggesting that [semaglutides] therapeutic effects arise from overlapping neurobiological mechanisms that modulate both metabolic regulation and reward-related pathways shared between obesity and alcohol use disorder. The team concluded: Findings from this trial provide support for broadening the indication for semaglutide to [include] AUD in patients with a BMI of 30 or greater, which could benefit millions. About 890 million adults globally have a BMI over 30, and in the U.S., 8 million adults are estimated to have obesity and high alcohol consumption
97 Patients with SONFH exhibit elevated lipid levels, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and an increased LDL/high-density lipoprotein (HDL) ratio
Researchers are responsible for ensuring their work complies with all applicable institutional, provincial, and federal regulations
